Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
- Primary : To determine the safety profile of each treatment group. - Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.
Critère d'inclusion
- Non-Small Cell Lung Carcinoma